Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 9Thoracic 1Sarcoma 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 34Pheochromocytoma 4Paraganglioma 4Carcinoma, Neuroendocrine 4Sarcoma 3Pancreatic Neoplasms 3Neoplasms 3Meningioma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Carcinoid Tumor 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Melanoma 2Medulloblastoma 2Liver Neoplasms 2Insulinoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Digestive System Neoplasms 2Colonic Neoplasms 2

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × NET × 30 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡